[Pubmed] The prognosis of MG patients with different thymic pathology: a multicenter retrospective cohort study

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6507
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Mac OS X Safari

[Pubmed] The prognosis of MG patients with different thymic pathology: a multicenter retrospective cohort study

Message par RSS-Bot »


BMC Med. 2025 Dec 16;23(1):685. doi: 10.1186/s12916-025-04509-w.

ABSTRACT

BACKGROUND: To identify the associations between thymic pathology and the prognosis of myasthenia gravis (MG) patients.

METHODS: In this multicenter retrospective study, 1,254 myasthenia gravis (MG) patients who underwent thymectomy across four clinical centers were included. Participants were categorized by thymic pathology into thymomatous and non-thymomatous groups. Primary outcome was postoperative deterioration. Secondary outcomes comprised the proportion of patients achieving minimal manifestation status (MMS) within the first year after surgery and conversion from ocular MG (OMG) to generalized MG (GMG) within 2 years of symptom onset. Subgroup analyses assessed associations between world health organization (WHO) pathological type (both groups) or Masaoka stage (thymoma patients) and prognosis.

RESULTS: Thymomas were associated with an increased risk of deterioration in both Cox regression (adjusted HR = 1.40 [1.18, 1.66], p < 0.001) and logistic regression analyses (1-year deterioration: adjusted OR = 1.59 [1.15, 2.20], p = 0.005; 3-year deterioration: adjusted OR = 1.40 [1.01, 1.94], p = 0.047). Additionally, thymomas were linked to a higher conversion rate (adjusted OR = 2.37 [1.15, 4.86], p = 0.019). However, thymoma showed no significant association with MMS (adjusted p = 0.682). In the thymoma subgroup, neither pathological type nor Masaoka stage was significantly associated with deterioration (pathological type: 1-year p = 0.069, 3-year p = 0.220; Masaoka stage: 1-year p = 0.944, 3-year p = 0.909), first-year MMS attainment (pathological type: p = 0.067; Masaoka stage: p = 0.579), or conversion rate (pathological type: p = 0.606; Masaoka stage: p = 0.163). Similarly, in the nonthymomatous group, WHO pathological type was not significantly correlated with deterioration (1-year p = 0.806, 3-year p = 0.654), MMS achieved (p = 0.940), or conversion (p = 0.755).

CONCLUSIONS: This study demonstrated an association between thymoma and higher risks of clinical deterioration, which was independent of WHO pathological type or Masaoka stage.

PMID:41402829 | DOI:10.1186/s12916-025-04509-w


Source: https://pubmed.ncbi.nlm.nih.gov/4140282 ... 22+67771e2
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »